Celsion Corporation receives FDA fast track designation for GEN-1 in advanced ovarian cancer


22 February 2021 - Designation provides potential for an expedited regulatory review..

Celsion Corporation today announced that it has received fast track designation from the U.S. FDA for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy currently in Phase II development for the treatment of advanced ovarian cancer. 

GEN-1 was designed using TheraPlas, Celsion's proprietary, synthetic, non-viral nanoparticle delivery system platform.

Read Celsion press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track